Skip to main content
Premium Trial:

Request an Annual Quote

High Dollar Donations for Genomics

Research programs focused on genomic medicine are becoming the darlings of deep-pocketed donors looking to advance understanding human diseases and developing new treatments for them, Kristina Strain of Inside Philanthropy writes.

For such funders, genomics is a smart investment as its two driving goals are to dig into the genetic and molecular basis of many of the diseases and disorders that plague humanity and then to use this newfound genomic knowledge to develop treatments that target disease precisely and are tailored for individuals.

Inside Philanthropy points out several massive recent financial injections into genomics spread across the US:

Philanthropist Ernest Rady gave the Rady Children's Hospital $120 million for a new pediatric genomic center that will investigate the genetic causes of specific rare birth defects that can hinder or even cut short children's lives.

Ted Stanley last month gave $650 million to the Broad Institute for genomics research into mental health and psychiatric disorders, such as bipolar disorder and schizophrenia.

The "subprime credit card king" and philanthropist T. Denny Sanford has pumped $125 million to Sanford Health to establish Sanford Imagenetics, which seeks to integrate genomic medicine into adult primary care and to train medical practitioners and researchers how to use these techniques and tools.

And the Helmsley Charitable Trust also has given the Salk Institute $42 million to found a new center for genomic medicine, Strain says, noting that the foundation has taken a "pet interest" in genomic medicine and is increasingly investing more into research focused on the genetic basis of IBD.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.